CTAS vs SYRE · P/E 51, rev $11.26B vs $7.60B cap
Cintas Corporation (CTAS) versus Spyre Therapeutics Inc. (SYRE) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Spyre Therapeutics Inc. (SYRE) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported SYRE revenue for 2025-12-31 was $0. Net income was -$155.2M. SYRE currently screens at market cap $7.60B.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. SYRE currently screens at market cap $7.60B.
Not investment advice. Open the CTAS and SYRE stock pages for the full models.
Not investment advice.